N/A
Completed N=200
Depression and Anxiety in Rheumatoid Arthritis
Source: ClinicalTrials.gov NCT02122406 ↗Enrolled (actual)
200
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcomePrimary: Hospital Anxiety and Depression Scale (HADS) — 107; 46; 20; 27 participants
Summary
The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hospital Anxiety and Depression Scale (HADS) |
107; 46; 20; 27 | — |
Eligibility Criteria
Inclusion Criteria
- age >18 years
- diagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria
- being able to compile questionnaire
- current treatment with biological disease-modifying antirheumatic drug
Exclusion Criteria
- Current treatment for anxiety or depressive disorder
Data sourced from ClinicalTrials.gov (NCT02122406). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.